These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 25394091)

  • 1. Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.
    Wiltshire CS; Lamorde M; Scherrer A; Musaazi J; Corti N; Allan B; Nakijoba R; Nalwanga D; Henning L; Von Braun A; Okware S; Castelnuovo B; Kambugu A; Fehr J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19585. PubMed ID: 25394091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of enteral antituberculosis drugs in patients requiring intensive care.
    Koegelenberg CF; Nortje A; Lalla U; Enslin A; Irusen EM; Rosenkranz B; Seifart HI; Bolliger CT
    S Afr Med J; 2013 Apr; 103(6):394-8. PubMed ID: 23725959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
    Tappero JW; Bradford WZ; Agerton TB; Hopewell P; Reingold AL; Lockman S; Oyewo A; Talbot EA; Kenyon TA; Moeti TL; Moffat HJ; Peloquin CA
    Clin Infect Dis; 2005 Aug; 41(4):461-9. PubMed ID: 16028152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.
    Kibiki GS; Mulder B; Dolmans WM; de Beer JL; Boeree M; Sam N; van Soolingen D; Sola C; van der Zanden AG
    BMC Microbiol; 2007 May; 7():51. PubMed ID: 17540031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.
    Avihingsanon A; van der Lugt J; Singphore U; Gorowara M; Boyd M; Ananworanich J; Phanuphak P; Burger D; Ruxrungtham K
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1170-6. PubMed ID: 22250979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay.
    Shah NS; Moodley P; Babaria P; Moodley S; Ramtahal M; Richardson J; Heysell S; Li X; Moll A; Friedland G; Sturm AW; Gandhi NR
    Am J Respir Crit Care Med; 2011 May; 183(10):1427-33. PubMed ID: 21297071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
    Wejse C; Furtado A; Camara C; Lüneborg-Nielsen M; Sodemann M; Gerstoft J; Katzenstein TL
    Int J Infect Dis; 2013 Oct; 17(10):e907-12. PubMed ID: 23816410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs.
    Bhutani H; Singh S; Jindal KC; Chakraborti AK
    J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.